Opinion|Videos|September 4, 2024
Navigating SG-related Diarrhea
Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please comment on your absolute neutrophil count cutoff for dose reductions and/or delay of sacituzumab govitecan (SG) therapy.
- How do you manage subsequent doses for patients who experienced febrile neutropenia with the previous cycle?
- How often do you see diarrhea (associated with SG) in your clinical practice? How does it compare to the rates reported in clinical trials (ASCENT, TROPiCS-02)?
- Are there risk factors that can predict those who are at higher risk for developing diarrhea?
- Are there any situations where you would consider testing for UGT1A1*28 homozygosity?
- Please comment on how you typically manage SG-related diarrhea.
- Are you utilizing prophylactic atropine or loperamide to prevent cholinergic syndrome prior to Cycle 1 of SG?
- Please comment on your management strategy for SG-related diarrhea (any similarities vs differences).
Advertisement
Related to this article
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.
Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The top 5 OncLive TV videos of the week.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
3
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
4
Japan Approves On-Body Injector for Subcutaneous Isatuximab in Multiple Myeloma
5